Medscape
The US Food and Drug Administration (FDA) has approved Cobenfy (Bristol Myers Squibb), a first-in-class antipsychotic approved for schizophrenia. The drug targets cholinergic receptors as opposed to dopamine receptors, which has been the standard of care for more than 30 years. It combines xanomeline, an oral muscarinic cholinergic receptor agonist and trospium chloride…
Read More
FDA OKs First-in-Class Antipsychotic for Schizophrenia
Dion Serna
13:19
The US Food and Drug Administration (FDA) has approved Cobenfy (Bristol Myers Squibb), a first-in-class antipsychotic approved for schizophrenia. The drug targets cholinergic receptors as opposed to dopamine receptors, which has been the standard of care for more than 30 years. It combines xanomeline, an oral muscarinic cholinergic receptor agonist and trospium chloride…
